The #FDA has approved #selumetinib for #pediatric patients ≥1 year of age with #neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. Learn more about the expanded #approval here: https://t.co/X8W2uWmnEj

What is it like to transition from being a #fellow to being an #oncology #attending? Watch as @mhadfield30 and @TanejaMD share their biggest lessons, surprises, and insights from their first year in independent practice! Watch here! https://t.co/HOgXisILLC #hemonc #fellowship

The #FDA has approved #gemcitabine intravesical system for the treatment of adults with bacillus Calmette-Guérin (BCG)–unresponsive non–muscle invasive #BladderCancer. Learn more about the #approval and the #SunRISe1 trial that led to it here: https://t.co/qZbEWbp0AD

In this month’s blog, @WaqasHaqueMD explores #ASCOmind for abstract summarization (@ASCO), new recommendations for AI-powered clinical trial matching, and @Artera_io's prognostic test paving the way for personalized medicine in prostate cancer. Read here! https://t.co/BTt2LuUlKV

#ASCOmind is a novel #AI framework designed to help synthesize the vast amount of data presented at @ASCO meetings. Here, @WaqasHaqueMD speaks with Xiaoyan Wang, PhD (@Tulane) and @WilliamOhMD (@YaleMed) about its development and benefits. Watch here! https://t.co/VvedysNncM

In a recent online activity provided by @i3health, clinicians’ #knowledge and #proficiency were challenged regarding practice-changing advancements in the management of #hemophilia. Check out the activity #outcomes and what was learned here: https://t.co/UjeHccfsXC

Dr. Patrick Wen of @DanaFarber discusses the recent #FDA accelerated #approval of #dordaviprone. Tune in to hear more about the #clinical context, trial data, implications for practice, and future directions in #glioma treatment. Watch here: https://t.co/2P4yLEg5kv #oncology

August is #SummerSunSafetyMonth! Dr. Matthew Hadfield shares guidance on UV biology and carcinogenesis, the role and safety profile of sunscreens, counseling strategies for diverse patient populations, and the power of #prevention. Watch here! https://t.co/jOP9jFgnb5 #SunSafety

Today is #WorldBreastCancerResearchDay. Watch as @connievisovsky1 shares her work investigating the impact of #CIPN in #BreastCancer and the role of targeted #exercise interventions to improve gait, balance, and quality of life. Watch here! https://t.co/4Mtgz5Aprq #bcsm

The #FDA granted accelerated approval to #zongertinib for unresectable or metastatic non-squamous #NSCLC whose tumors harbor #HER2 tyrosine kinase domain (#TKD) activating mutations. Learn more about the #approval and the #BeamionLUNG1 trial here: https://t.co/37xT7x5O5k

In this edition of The Way Ahead, @WaqasHaqueMD delves into innovations and considerations in both digital and social technology, including #AI-discovered drugs in clinical trials, the need for human oversight, and the CHALLENGE exercise trial. Read here! https://t.co/12FCy4jWB9

The FDA's decision to withhold approval of #RP1 (vusolimogene oderparepvec), an oncolytic virus therapy for advanced #melanoma, has come as a surprise to the oncology community. Here, Matthew Hadfield and Justin Moser share their perspectives. Watch here! https://t.co/ggASjUdJzW

#GeneticCounseling is a crucial component of #oncology #PrecisionMedicine. In this follow-up to their @i3health activity, @FilipaLynce (@harvardmed) and Catherine Skefos (@MDAndersonNews) share new advances that have occurred in the field. Watch here! https://t.co/WVy72TICsK

Watch as @HundalJasmin, Hem/Onc Fellow at @ClevelandClinic, shares highlights from #MASCC25 (@CancerCareMASCC), including key themes in #supportive care, #occupational health, #financial toxicity, and the growing role of patient #advocacy. Watch here! https://t.co/9Av2thDJ0A

Today is #WorldLungCancerDay! 🫁🥼 Unlock the latest breakthroughs in #HER2-mutant #NSCLC with @JuliaRotow! Discover new advances, clinical insights, and what’s next for targeted therapies. Watch here: https://t.co/UzSsizsb7j #Oncology #LungCancer #CancerResearch

After #ASCO25, @HundalJasmin sat down to describe two trials, #SERENA6 and #VERITAC2, and their potential to change how we approach endocrine resistance and treatment sequencing in HR-positive, HER2-negative advanced #BreastCancer. Watch here! https://t.co/34u69BLOo5 #BCsm

In this bonus video for i3 Health's #CME activity on multicancer early detection (#MCED) testing, @WaqasHaqueMD shares his perspectives as a fellow on how MCED is transforming cancer screening and considerations for implementing into practice. Watch here! https://t.co/ny1G68l064

Recently, @i3health provided an #educational activity that challenged clinicians’ #proficiency in the use of #immunotherapy for recurrent/metastatic head and neck squamous cell #carcinoma (#HNSCC). Learn more about the #outcomes and knowledge gains here: https://t.co/EyH4BMTJKg

In this Letter From the Editor, @RahulBanerjeeMD reflects on the groundbreaking findings of the CHALLENGE trial, which show that structured #exercise interventions can yield survival benefits rivaling those of established #cancer therapies. Read here! https://t.co/fmKRbGjKXL

In honor of #SarcomaAwarenessMonth in July, @richardriedelmd and @candace_haddox share updates to their @i3health Dedifferentiated #Liposarcoma (#DDLPS) Task Force. Watch here: https://t.co/ANoTxnjKn5 And view the full Task Force and position statement: https://t.co/KYYy7dthHK